Logo

endometrial cancer

Arquer Dx Developing Urine-Based Protein Biomarker Tests to Detect Bladder, Endometrial Cancers
Premium

Arquer's assays use mouse monoclonal antibodies to detect levels of MCM5 proteins in cells exfoliated into urine to detect either bladder or endometrial cancers.

FDA Approves GlaxoSmithKline's Jemperli, Roche’s Ventana CDx for dMMR Solid Cancers

The approval expands the label for GSK's anti-PD-1 agent dostarlimab, which the FDA initially approved in April for patients with dMMR endometrial cancers.

FDA Approves GSK's Jemperli With Ventana CDx for dMMR Endometrial Cancer

The FDA also approved the Ventana MMR RxDx panel as a companion diagnostic to select endometrial cancer patients for treatment with dostarlimab.

Promega to Develop MSI Assay as CDx for Incyte Endometrial Cancer Drug

Promega will develop its microsatellite instability assay as a companion diagnostic for Incyte's anti-PD-1 drug candidate retifanlimab in endometrial cancer.

Cancer, Pathology Organizations Developing Clinical Guidelines for MMR, MSI Testing

The groups have written draft recommendations and are now asking for public comment from pathologists and other stakeholders.